Cargando…

COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report

INTRODUCTION: Large-scale vaccination is considered one of the most effective strategies to control the pandemic of COVID-19. Since its start, different complications have been described thought to be related to vaccination. Here, we present a rare case where encephalopathy, myocarditis, and thrombo...

Descripción completa

Detalles Bibliográficos
Autores principales: Asaduzzaman, Md, Purkayastha, Bidrum, Alam, M. M. Jahangir, Chakraborty, Shishir Ranjan, Roy, Soumitra, Ahmed, Nasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080027/
https://www.ncbi.nlm.nih.gov/pubmed/35561428
http://dx.doi.org/10.1016/j.jneuroim.2022.577883
_version_ 1784702691052617728
author Asaduzzaman, Md
Purkayastha, Bidrum
Alam, M. M. Jahangir
Chakraborty, Shishir Ranjan
Roy, Soumitra
Ahmed, Nasad
author_facet Asaduzzaman, Md
Purkayastha, Bidrum
Alam, M. M. Jahangir
Chakraborty, Shishir Ranjan
Roy, Soumitra
Ahmed, Nasad
author_sort Asaduzzaman, Md
collection PubMed
description INTRODUCTION: Large-scale vaccination is considered one of the most effective strategies to control the pandemic of COVID-19. Since its start, different complications have been described thought to be related to vaccination. Here, we present a rare case where encephalopathy, myocarditis, and thrombocytopenia developed simultaneously following the second dose of Pfizer-BioNTech mRNA vaccine (BNT162b2). CASE PRESENTATION: A 15-years-old female presented with fever, altered consciousness, and convulsions after taking the second shot of the vaccine. Clinical and laboratory workup was notable for the presence of thrombocytopenia and myocarditis. No alternative causes of encephalitis were found. The patient responded significantly to methylprednisolone suggesting underlying immune pathogenesis responsible for the clinical features. The diagnostic criteria for possible autoimmune encephalitis were also fulfilled. CONCLUSION: Although rare, the clinician should be aware of the possible adverse events following COVID-19 vaccination. Further research with large pooled data is needed to get more insight into its pathogenesis and causal relationship.
format Online
Article
Text
id pubmed-9080027
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-90800272022-05-09 COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report Asaduzzaman, Md Purkayastha, Bidrum Alam, M. M. Jahangir Chakraborty, Shishir Ranjan Roy, Soumitra Ahmed, Nasad J Neuroimmunol Short Communication INTRODUCTION: Large-scale vaccination is considered one of the most effective strategies to control the pandemic of COVID-19. Since its start, different complications have been described thought to be related to vaccination. Here, we present a rare case where encephalopathy, myocarditis, and thrombocytopenia developed simultaneously following the second dose of Pfizer-BioNTech mRNA vaccine (BNT162b2). CASE PRESENTATION: A 15-years-old female presented with fever, altered consciousness, and convulsions after taking the second shot of the vaccine. Clinical and laboratory workup was notable for the presence of thrombocytopenia and myocarditis. No alternative causes of encephalitis were found. The patient responded significantly to methylprednisolone suggesting underlying immune pathogenesis responsible for the clinical features. The diagnostic criteria for possible autoimmune encephalitis were also fulfilled. CONCLUSION: Although rare, the clinician should be aware of the possible adverse events following COVID-19 vaccination. Further research with large pooled data is needed to get more insight into its pathogenesis and causal relationship. Elsevier B.V. 2022-07-15 2022-05-08 /pmc/articles/PMC9080027/ /pubmed/35561428 http://dx.doi.org/10.1016/j.jneuroim.2022.577883 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Asaduzzaman, Md
Purkayastha, Bidrum
Alam, M. M. Jahangir
Chakraborty, Shishir Ranjan
Roy, Soumitra
Ahmed, Nasad
COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report
title COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report
title_full COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report
title_fullStr COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report
title_full_unstemmed COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report
title_short COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case report
title_sort covid-19 mrna vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: a case report
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080027/
https://www.ncbi.nlm.nih.gov/pubmed/35561428
http://dx.doi.org/10.1016/j.jneuroim.2022.577883
work_keys_str_mv AT asaduzzamanmd covid19mrnavaccineassociatedencephalopathymyocarditisandthrombocytopeniawithexcellentresponsetomethylprednisoloneacasereport
AT purkayasthabidrum covid19mrnavaccineassociatedencephalopathymyocarditisandthrombocytopeniawithexcellentresponsetomethylprednisoloneacasereport
AT alammmjahangir covid19mrnavaccineassociatedencephalopathymyocarditisandthrombocytopeniawithexcellentresponsetomethylprednisoloneacasereport
AT chakrabortyshishirranjan covid19mrnavaccineassociatedencephalopathymyocarditisandthrombocytopeniawithexcellentresponsetomethylprednisoloneacasereport
AT roysoumitra covid19mrnavaccineassociatedencephalopathymyocarditisandthrombocytopeniawithexcellentresponsetomethylprednisoloneacasereport
AT ahmednasad covid19mrnavaccineassociatedencephalopathymyocarditisandthrombocytopeniawithexcellentresponsetomethylprednisoloneacasereport